KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy

KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy

User Photo
Annual-Meeting

1 year
161 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy.
Up Next Autoplay